Avinger reported Q3 2024 results with revenue of $1.7 million and a gross margin of 26%. The company implemented a cost reduction program, which led to a 15% improvement in net loss and a 12% improvement in adjusted EBITDA compared to the previous quarter. They also filed an IDE pre-submission package with the FDA for their coronary CTO-crossing system.

Avinger reported Q2 2024 revenue of $1.8 million with a gross margin of 20%. The company streamlined operating costs and is advancing its coronary product line development, with IDE submission anticipated in Q3 2024. They also secured up to $24 million in additional growth financing and appointed Thomas Davis as Chief Medical Officer.

Avinger reported first quarter 2024 revenue of $1.9 million with a gross margin of 18%. The company is advancing its new OCT-Guided Coronary Product Development and initiated Phase III verification and validation studies for its image-guided coronary CTO-crossing system.

Avinger reported a Q4 revenue of $1.9 million, a 5% sequential increase, and a gross margin of 20%. The company expanded its sales team by more than 25% and deepened its presence in key markets. Avinger also announced a strategic financing and partnership agreement with Zylox-Tonbridge.

Avinger reported third quarter revenue of $1.8 million with a gross margin of 21%. The company is expanding its sales team to drive revenue growth in 2024 and advancing the development of a coronary CTO-crossing system.

Avinger, Inc. reported second quarter 2023 results, featuring revenue of $2.0 million and a gross margin of 30%. The company received 510(k) clearance for Tigereye ST and Pantheris LV, and advanced the development of its coronary CTO-crossing system.

Avinger, Inc. reported first quarter 2023 results with a revenue of $1.9 million and a gross margin of 34%. The company received 510(k) clearance for Tigereye ST and filed a 510(k) submission for the new Pantheris LV. They maintained a cash position of $10.4 million at the end of the quarter.

Avinger reported Q4 2022 revenue of $2.0 million with a gross margin of 34%. The company maintained a strong cash position of $14.6 million. They are advancing multiple product and clinical programs and submitted all requested documentation related to the 510(k) submission for their new Tigereye ST CTO-crossing catheter and are preparing to initiate limited launch pending FDA clearance.

Avinger reported a revenue of $2.3 million for the third quarter of 2022, representing a 6% increase from the second quarter. The gross margin was 35%, reflecting increased revenue and capital sales. The company's cash position increased to $17.3 million at the end of the quarter.

Avinger reported a revenue of $2.1 million for the second quarter of 2022, representing a 13% increase from the first quarter of 2022. The company's gross margin was 31%, with increased revenue levels driving a 3 percentage point improvement from the first quarter. They maintained a strong cash position of $16.0 million at June 30, 2022.

Avinger, Inc. reported a decrease in revenue for Q1 2022 compared to Q1 2021, with $1.9 million versus $2.6 million, impacted by COVID-19 related hospital constraints. The company maintained a strong cash position of $20.0 million and progressed the development of new catheter line extensions.

Avinger, Inc. reported fourth-quarter revenue of $2.4 million and full-year 2021 revenue of $10.1 million. The company's fourth-quarter results were impacted by hospital constraints on procedural volume and hospital staffing shortages related to the resurgence of COVID-19.

Avinger reported a 3% increase in revenue to $2.4 million for Q3 2021 compared to the prior year. Gross margin remained consistent at 34%. The company made progress on strategic initiatives, including filing 510(k) applications for new products and expanding to new clinical sites, but faced challenges due to COVID-19 related hospital access limitations.

Avinger, Inc. reported strong revenue gains for both Pantheris atherectomy and image-guided CTO product lines, with total revenue increasing 91% year-over-year to $2.8 million. The company also filed two new 510(k) submissions to support future growth opportunities and maintained a strong cash position of $26.7 million.

Avinger reported a 19% sequential increase in total revenue to $2.7 million, driven by a 38% sequential increase in image-guided CTO revenue from the limited launch of Tigereye. Gross margin rose to 36%, and the company ended the year with $22.2 million in cash and cash equivalents.